Neratinib Maleate Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 40 mg
Reference Brands: Nerlynx (USA/EU)
Category:
Oncology Cancer Care
Neratinib maleate is available in Tablets
and strengths such as 40 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Neratinib maleate is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Neratinib maleate can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Neratinib maleate is the maleate salt form of neratinib, an orally available, quinazoline-based small-molecule inhibitor with potent antineoplastic activity. It functions as an irreversible inhibitor of receptor tyrosine kinases, specifically human epidermal growth factor receptor 2 (HER2/ERBB2) and epidermal growth factor receptor (EGFR), both of which are commonly overexpressed or mutated in various types of cancer. These receptors play a crucial role in tumor cell proliferation, survival, and vascularization.
Following oral administration, neratinib maleate selectively targets and covalently binds to cysteine residues located within the ATP-binding pockets of HER2 and EGFR. This irreversible binding leads to sustained inhibition of receptor activity, effectively blocking downstream signal transduction pathways involved in cancer cell growth. As a result, neratinib induces cell cycle arrest and promotes programmed cell death (apoptosis) in tumor cells that express HER2 and EGFR.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing